You are here: Industry Insights > Epizyme

News List

Epizyme’s Tazverik secures FDA approval to treat follicular lymphoma pharmaceutical-technology
June 22, 2020
Epizyme has secured accelerated approval from the US Food and Drug Administration (FDA) for Tazverik to treat relapsed / refractory follicular lymphoma.
Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Follicular Lymphoma drugs
December 20, 2019
Epizyme, Inc., a late-stage biopharmaceutical company developing novel epigenetic therapies, announced that it has submitted a New Drug Application (NDA) to ...
Epizyme Announces NDA Acceptance, Priority Review for Tazemetostat americanpharmaceuticalreview
July 26, 2019
Epizyme announced the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for accelerated approval of tazemetostat, its lead investigational agent.
Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma drugs
June 13, 2019
Epizyme Submits New Drug Application to the U.S. FDA for Tazemetostat for the Treatment of Patients with Epithelioid Sarcoma.
Boehringer partners with Epizyme to develop new cancer therapies pharmaceutical-technology
November 19, 2018
Boehringer Ingelheim has formed a global alliance with US-based biopharmaceutical firm Epizyme for the research, development and commercialisation of new potential cancer treatments.
Boehringer signs $300 million deal with Epizyme over epigenetic cancer treatment pharmatimes
November 19, 2018
German firm Boehringer Ingelheim and the Massachusetts-based biotech Epizyme have announced that they will collaborate on the development of novel, small molecule
Epizyme Earns $10 Million Payment from GSK for GLP Toxicology Studies americanpharmaceuticalreview
May 05, 2017
Epizyme announced it earned a $10 million milestone payment from GlaxoSmithKline (GSK). The milestone payment follows GSK’s initiation of GLP toxicology studies for a methyltransferase inhibitor discovered by Epizyme and licensed to GSK.
Epizyme Earns $10M GSK Milestone contractpharma
May 05, 2017
Initiates GLP tox studies with novel methyltransferase inhibitor